Abstract Number: 1817 • 2019 ACR/ARP Annual Meeting
Arthropathy of Down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change
Background/Purpose: Incidence and prevalence of arthropathy of Down syndrome (A-DS) is increased. It is rarely recognised at onset and remains under-diagnosed. Children with A-DS are therefore…Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…Abstract Number: 773 • 2019 ACR/ARP Annual Meeting
Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation
Background/Purpose: Progression of Juvenile Idiopathic Arthritis (JIA) can lead to growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a key role in the pathogenesis…Abstract Number: 1883 • 2019 ACR/ARP Annual Meeting
Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
Background/Purpose: Despite a broad range of available therapeutics, pain remains poorly treated in many juvenile idiopathic arthritis (JIA) patients1-2. For some patients, the level of pain…Abstract Number: 2712 • 2019 ACR/ARP Annual Meeting
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…Abstract Number: 779 • 2019 ACR/ARP Annual Meeting
The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants
Background/Purpose: IL2RA has been identified as a JIA-associated risk locus using both candidate gene and genetic fine mapping approaches. However, numerous gene expression studies comparing…Abstract Number: 1920 • 2019 ACR/ARP Annual Meeting
School Nurse Education for Juvenile Idiopathic Arthritis
Background/Purpose: There is a paucity of literature on the challenges children with JIA face at school. Despite treatment advances, children with JIA often rate their…Abstract Number: 2714 • 2019 ACR/ARP Annual Meeting
Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry
Background/Purpose: Inactive disease is the stated goal of treatment in juvenile idiopathic arthritis (JIA) and is typically measured by a composite score that combines several…Abstract Number: 781 • 2019 ACR/ARP Annual Meeting
Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?
Background/Purpose: Down syndrome associated Arthritis (DA) is 20 times more common than JIA. It is an erosive, polyarticular RF negative arthritis with predominance in the…Abstract Number: 1921 • 2019 ACR/ARP Annual Meeting
Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and many medications are available to control the disease. While physician-reported adverse…Abstract Number: 2715 • 2019 ACR/ARP Annual Meeting
Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common childhood onset inflammatory arthritis. The last estimates of incidence of this disease in the United Kingdom…Abstract Number: 782 • 2019 ACR/ARP Annual Meeting
Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion
Background/Purpose: Activated T cells are involved in the pathogenesis of the synovitis in oligoarticular Juvenile Idiopathic Arthritis (o-JIA). T cell activation is counter-balanced via co-inhibitory…Abstract Number: 1923 • 2019 ACR/ARP Annual Meeting
Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials
Background/Purpose: Tocilizumab (TCZ) was approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) based on the results of…Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…Abstract Number: 785 • 2019 ACR/ARP Annual Meeting
Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience
Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 19
- Next Page »